Intellia Therapeutics Q4 collaboration revenue rises, net loss narrows

INTELLIA THERAPEUTICS

26/02/2026 12:37

Overview

Biopharmaceutical firm's Q4 collaboration revenue rose yr/yr

Net loss for Q4 narrowed compared to last year

Company ended 2025 with $605 mln in cash and securities

Outlook

Intellia expects HAELO Phase 3 data by mid-2026, BLA submission in second half of 2026

Company plans U.S. launch of lonvo-z for HAE in first half of 2027

Intellia expects MAGNITUDE-2 enrollment completion by second half of 2026

Result Drivers

LONVO-Z PHASE 3 PROGRESS - Intellia completed patient enrollment for the HAELO Phase 3 trial of lonvo-z, with topline data expected by mid-2026

NEX-Z CLINICAL HOLDS - FDA lifted clinical hold on MAGNITUDE-2 trial for nex-z, but MAGNITUDE trial remains on hold

INCREASED COLLABORATION REVENUE - Q4 collaboration revenue rose due to termination of SparingVision agreement and Regeneron cost reimbursements

Company press release: ID:nGNXbGMYg5

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Collaboration Revenue
$23.02 mln
Q4 Net Income
-$95.79 mln
Q4 Basic EPS
-$0.83
Q4 Operating Expenses
$121.73 mln
Q4 Operating Income
-$98.71 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 10 "strong buy" or "buy", 12 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Intellia Therapeutics Inc is $14.00, about 4.3% above its February 25 closing price of $13.42

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)